Clinical System for Arterial Tissue Characterization

动脉组织表征的临床系统

• 批准号: 6736538
• 负责人: STEPHEN FREDERICK FULGHUM
• 金额: $ 9.98万
• 依托单位: NEWTON LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-02-01 至 2005-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6736538
• 关键词: atherosclerotic plaque; biomedical equipment development; cardiovascular disorder diagnosis; diagnosis design /evaluation; fluorescence spectrometry; fluorescent dye /probe; optics

DESCRIPTION (provided by applicant): Atherosclerosis is the leading cause of death in industrialized countries, worldwide. In the United States, myocardial infarctions, almost entirely attributable to coronary artery atherosclerosis, account for 20 to 25% of all deaths. Therapies are available, but no reliable methods can predict in advance which lesions will progress. One major reason is that in situ biopsies of blood vessels is difficult and risky, so histopathology cannot be used routinely to provide information about the state of diseased vessels. A substantial literature of in vitro studies show that fluorescence spectroscopy of arterial walls can distinguish between normal, atherosclerotic and calcified atherosclerotic plaque. Few successful in vivo studies have been done, however, for several reasons. One reason is the lack of a suitable optical probe. Another reason is that hemoglobin absorption often distorts the fluorescence signatures to the point where they cannot be properly analyzed. NLI proposes to address these limitations by designing, fabricating and testing a new side-looking optical probe which will measure, in vivo, both fluorescence and reflectance from arterial tissue. From these two measurements intrinsic fluorescence spectra, undistorted by scattering and absorption processes can be obtained, which will greatly improve the reliability of the optical diagnosis.

描述(由申请人提供)：动脉粥样硬化是全球工业化国家的主要死亡原因。在美国，心肌梗死几乎完全由冠状动脉粥样硬化引起，占所有死亡人数的20%至25%。治疗方法是可用的，但没有可靠的方法可以提前预测哪些病变会进展。一个主要原因是血管的原位活组织检查既困难又有风险，因此组织病理学不能常规地用来提供有关病变血管状态的信息。大量的体外研究文献表明，动脉壁荧光光谱可以区分正常、动脉粥样硬化和钙化的动脉粥样硬化斑块。然而，由于几个原因，几乎没有成功的体内研究。原因之一是缺乏合适的光学探头。另一个原因是，血红蛋白的吸收经常会扭曲荧光信号，以至于无法正确分析它们。NLI建议通过设计、制造和测试一种新的侧视光学探头来解决这些限制，该探头将在体内测量动脉组织的荧光和反射率。从这两个测量中可以得到不受散射和吸收过程失真的本征荧光光谱，这将大大提高光学诊断的可靠性。